86 articles in this topic
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
A completed Phase 2 trial tests UCPVax cancer vaccine combined with atezolizumab in cervical, anal, and head-and-neck cancers.
A completed phase I trial tests regorafenib plus dual checkpoint inhibitors in 39 patients with hard-to-treat metastatic colorectal cancer.
A completed Phase 2 trial tests nivolumab plus ipilimumab in CDK12-mutant metastatic prostate and solid tumors across 56 patients.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
A completed Phase II trial tests whether combining two checkpoint inhibitors can safely and effectively treat melanoma that has spread to the brain.
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Engineered immune cells target liver cancer protein in phase I safety study, though trial ended early with 10 patients.
Phase 1 trial tests innovative immunotherapy for multiple myeloma and lymphoma patients who didn't respond to standard treatments.
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
Small trial tests novel three-drug approach combining immune checkpoint inhibitor, vaccine, and inflammation blocker for metastatic cancers.
Study examines bone density loss in melanoma patients receiving immune-boosting cancer drugs like nivolumab and pembrolizumab.
